Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Mankind Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 2280.2, down 1.25% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 23541.1. The Sensex is at 75140.89, down 0.58%.Mankind Pharma Ltd has eased around 6.47% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has increased around 0.92% in last one month and is currently quoting at 26880.8, down 0.59% on the day. The volume in the stock stood at 1.21 lakh shares today, compared to the daily average of 3.25 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 2293.5, down 0.73% on the day. Mankind Pharma Ltd tumbled 12.59% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index.
The PE of the stock is 42.12 based on TTM earnings ending June 26.
Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., China, for the commercialisation of two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, in India.
Commenting on the partnership, Atish Majumdar, Senior President – Sales and Marketing, Mankind Pharma said, “China is rapidly emerging as a hub for innovative biopharmaceutical assets. Building on our partnerships for Insulin Aspart and Insulin Degludec, we remain focused on expanding our in-licensing pipeline from China. This partnership reinforces our commitment to expanding access to advanced therapies for patients in India while further strengthening our presence in the injectable diabetes segment.”
Domestic revenue (ex-Consumer Health) increased 11.0% YoY to Rs 3,180 crore, driven primarily by double digit growth in Mankind business and supported by strong growth in BSV specialty business.
The Consumer Healthcare Business has recorded revenue of Rs 246 crore (up 4% YoY), partly impacted by base effect of discontinued cash and carry business.
Revenue from International business increased by 29% YoY to Rs 605 crore in Q1FY27.
EBITDA improved by 24.7% YoY to Rs 1,060 crore while EBITDA margin expanded 250 basis points YoY to 26.3%
Profit before tax in Q1 FY27 stood at Rs 769 crore, up by 42% from Rs 540 crore in Q1 FY26.
'Our disciplined execution and strengthening business fundamentals, resulted in improvements across key operating and financial metrics in Q1FY27, laying the foundation to deliver long-term sustainable growth,' Mankind Pharma said in a statement.
In a seperate filing, Mankind Pharma informed that its board has approved the issuance of a corporate guarantee aggregating to Rs 150 crore in favour of various banks to secure the various types of credit facilities availed or proposed to be availed by the Bharat Serums and Vaccines (BSV) is a wholly owned subsidiary of the company.
The corporate guarantee will be treated as a contingent liability and commitment for the company to the extent of facility to be availed by the BSV.
Mankind Pharma is one of the largest pharmaceutical company in India. The company operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors.
The scrip shed 0.60% to end at Rs 2576.95 on the BSE today.
The board of Mankind Pharma at its meeting held on 11 July 2026, has inter-alia, considered and approved the:
Mankind Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2412.2, down 0.47% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.11% on the day, quoting at 23888.4. The Sensex is at 75882.34, down 0.17%.Mankind Pharma Ltd has gained around 6.53% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has increased around 6.66% in last one month and is currently quoting at 24659.2, up 0.16% on the day. The volume in the stock stood at 3.04 lakh shares today, compared to the daily average of 7.96 lakh shares in last one month.
The benchmark June futures contract for the stock is quoting at Rs 2429.3, down 0.46% on the day. Mankind Pharma Ltd tumbled 2.88% in last one year as compared to a 3.49% slide in NIFTY and a 15.46% spurt in the Nifty Pharma index.
The PE of the stock is 47.06 based on TTM earnings ending March 26.